Payment overview · 2025
General Payments
$4,580.59
184 reported records · 30 companies
Healthcare provider profile · identity verified
John O Lai, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DALY CITY, CA · NPI 1457398406
Verified facts
What the public records show
CMS Open Payments records show John O Lai, M.D. received $4,580.59 in general payments during 2025 across 184 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 55 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,001.33 | 21.9% | 30 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $478.08 | 10.4% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $353.63 | 7.7% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $298.25 | 6.5% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $284.60 | 6.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $277.24 | 6.0% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $247.57 | 5.4% | 10 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $237.46 | 5.2% | 11 | 2025 |
| CMP Pharma, Inc. | Unresolved — no canonical attribution shown | $221.68 | 4.8% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $189.42 | 4.1% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $161.43 | 3.5% | 6 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $105.04 | 2.3% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $89.78 | 2.0% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $77.78 | 1.7% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $61.68 | 1.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.87 | 1.3% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.55 | 1.2% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $49.98 | 1.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.29 | 0.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.51 | 0.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.34 | 0.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.53 | 0.7% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $29.09 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.34 | 0.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.09 | 0.6% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $26.03 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.83 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.06 | 0.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $22.93 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.18 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,580.59 | 184 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $473.76 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $457.82 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $401.34 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $256.25 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $256.25 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $247.57 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $236.90 | 6 | 2025 |
Source payment records
|
|||||
| Atorvaliq Normalized: atorvaliq |
Drug | CMP Pharma, Inc. | $221.68 | 9 | 2025 |
Source payment records
|
|||||
| carospir Normalized: carospir |
Drug | CMP Pharma, Inc. | $221.68 | 9 | 2025 |
Source payment records
|
|||||
| liqrev Normalized: liqrev |
Drug | CMP Pharma, Inc. | $221.68 | 9 | 2025 |
Source payment records
|
|||||
| norliqva Normalized: norliqva |
Drug | CMP Pharma, Inc. | $221.68 | 9 | 2025 |
Source payment records
|
|||||
| tadliq Normalized: tadliq |
Drug | CMP Pharma, Inc. | $221.68 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $207.29 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $206.59 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.07 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $189.42 | 8 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $185.79 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $169.25 | 7 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $105.76 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $105.04 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.31 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $99.29 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $89.78 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $80.05 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $77.78 | 3 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $77.78 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $63.46 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $61.68 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $61.68 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $60.87 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $59.51 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $58.67 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $53.55 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.25 | 2 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $41.29 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $35.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.34 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $30.74 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.53 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $29.09 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.09 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.45 | 2 | 2025 |
Source payment records
|
|||||
| AEQUALIS PERFORM Normalized: aequalis perform |
Device | Stryker Corporation | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 249 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 41 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
85 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
249 | 69 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
249 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1292 | 345 |
| Amlodipine Besylate | Amlodipine Besylate | 1162 | 322 |
| Metformin Hcl | Metformin Hcl | 706 | 191 |
| Losartan Potassium | Losartan Potassium | 675 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 394 | 90 |
| Lisinopril | Lisinopril | 393 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 362 | 92 |
| Omeprazole | Omeprazole | 345 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 282 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 268 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 267 | 78 |
| Simvastatin | Simvastatin | 267 | 78 |
| Allopurinol | Allopurinol | 260 | 71 |
| Furosemide | Furosemide | 259 | 74 |
| Pioglitazone Hcl | Pioglitazone Hcl | 251 | 66 |
| Jardiance | Empagliflozin | 249 | 69 |
| Finasteride | Finasteride | 212 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 201 | 69 |
| Atenolol | Atenolol | 196 | 53 |
| Eliquis | Apixaban | 195 | 39 |
| Famotidine | Famotidine | 180 | 57 |
| Lovastatin | Lovastatin | 178 | 44 |
| Metformin Hcl Er | Metformin Hcl | 175 | 58 |
| Carvedilol | Carvedilol | 174 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 170 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 44 |
| Januvia | Sitagliptin Phosphate | 156 | 34 |
| Gabapentin | Gabapentin | 148 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 39 |
| Tramadol Hcl | Tramadol Hcl | 137 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 34 |
| Montelukast Sodium | Montelukast Sodium | 122 | 30 |
| Azithromycin | Azithromycin | 115 | 95 |
| Donepezil Hcl | Donepezil Hcl | 113 | 19 |
| Benazepril Hcl | Benazepril Hcl | 112 | 30 |
| Glipizide | Glipizide | 106 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 24 |
| Ezetimibe | Ezetimibe | 96 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 69 |
| Lorazepam | Lorazepam | 86 | 22 |
| Linzess | Linaclotide | 85 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 17 |
| Farxiga | Dapagliflozin Propanediol | 77 | 19 |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 34 |
| Glimepiride | Glimepiride | 76 | 18 |
| Colchicine | Colchicine | 68 | 33 |
| Meloxicam | Meloxicam | 68 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 64 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 39 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Cephalexin | Cephalexin | 62 | 49 |
| Trazodone Hcl | Trazodone Hcl | 62 | 22 |
| Potassium Chloride | Potassium Chloride | 59 | 20 |
| Ketoconazole | Ketoconazole | 58 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 11 |
| Sertraline Hcl | Sertraline Hcl | 57 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 13 |
| Invokana | Canagliflozin | 52 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 27 |
| Amoxicillin | Amoxicillin | 50 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 15 |
| Latanoprost | Latanoprost | 49 | 12 |
| Megestrol Acetate | Megestrol Acetate | 49 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 49 | 12 |
| Clonazepam | Clonazepam | 48 | 11 |
| Risperidone | Risperidone | 46 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 15 |
| Glipizide Er | Glipizide | 44 | 13 |
| Valsartan | Valsartan | 44 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Ibuprofen | Ibuprofen | 40 | 12 |
| Mirtazapine | Mirtazapine | 40 | 12 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 38 | 11 |
| Prednisone | Prednisone | 38 | 16 |
| Baclofen | Baclofen | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Acarbose | Acarbose | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 11 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 12 |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,580.59 · 184 records | AstraZeneca Pharmaceuticals LP | AEQUALIS PERFORM, AIRSUPRA, ANDEXXA, AREXVY, Atorvaliq, BREZTRI, CAMZYOS, CAPVAXIVE, CREON, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FFRct, FLOWTRIEVER CATHETER, S, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, JASCAYD, KISUNLA, Kerendia, LEQVIO, LINZESS, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, REZDIFFRA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE, carospir, liqrev, norliqva, tadliq | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error